Andrew Stephen Moriarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Stephen Moriarty has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Dean McMillan
Department of Health Sciences, Hull York Medical School University of York York UK
7 shared publicationsShehzad Ali
Department of Health Sciences, University of York
6 shared publications- Simon Gilbody
Department of Health Sciences, University of York, York, UK
6 shared publications Carolyn A Chew-Graham
School of Medicine, Keele University
5 shared publicationsSimon Gilbody
Department of Health Sciences, Hull York Medical School University of York York UK
5 shared publications- Dean McMillan
Department of Health Sciences, University of York
4 shared publications
Latest Publications
- Open Access
- 31 July 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (757) , 377-380
Improving general practice appointment booking processes: bureaucratic justice and patient-centred reforms
‘Bureaucracy’ is a loaded term in general practice. In October 2024, UK Secretary of State for Health and Social Care, Wes Streeting, announced a ‘red tape challenge’ to cut down on general practice bureaucracy at the RCGP annual conference. But is cutting down on bureaucracy the right starting point to bring about positive change in general practice administration?
- 31 July 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (757) , 377-380
Open AccessImproving general practice appointment booking processes: bureaucratic justice and patient-centred reforms
‘Bureaucracy’ is a loaded term in general practice. In October 2024, UK Secretary of State for Health and Social Care, Wes Streeting, announced a ‘red tape challenge’ to cut down on general practice bureaucracy at the RCGP annual conference. But is cutting down on bureaucracy the right starting point to bring about positive change in general practice administration?
- Open Access
- 18 December 2024
- Published by Wiley in Health Expectations
- Vol. 27 (6) , e70059
The Value of Clinical Prediction Models in General Practice: A Qualitative Study Exploring the Perspectives of People With Lived Experience of Depression and General Practitioners
Introduction: Prediction models are increasingly being used to guide clinical decision making in primary care. There is a lack of evidence exploring the views of patients and general practitioners (GPs) in primary care around their use and implementation. We aimed to better understand the perspectives of GPs and people with lived experience of depression around the use of prediction models and communication of risk in primary care.Methods: Qualitative methods were used. Data were generated over 6 months (April to October 2022) through semi‐structured interviews with 23 people with lived experience of depression and 22 GPs. A multidisciplinary research team and Patient Advisory Group were involved throughout the study. Data were analysed inductively using thematic analysis.Results: GPs describe using prediction models in consultations only when the models are either perceived to be useful (e.g., because they help address an important clinical problem) or if GPs feel compelled to use them to meet financial or contractual targets. These two situations are not mutually exclusive, but if neither criterion is met, a model is unlikely to be used in practice. People with lived experience of depression and GPs reported that communication of model outputs should involve a combination of risk categories, numerical information and visualisations, with discussions being tailored to the individual patients involved. Risk prediction in a mental health context was perceived to be more challenging than for physical health conditions.Conclusion: Clinical prediction models are used in practice but thought must be given at the study development stage to how results will be presented and discussed with patients. Meaningful, embedded public and patient involvement and engagement are recommended when developing or implementing clinical prediction models.Patient or Public Contribution: We used a combination of embedded consultation and collaboration/co‐production in our approach to public and patient involvement in this study. A Patient Advisory Group made up of people with lived experience of depression were involved from study conception and contributed to study design, participant recruitment, interpretation of findings and dissemination (including in the preparation of this manuscript).
- 18 December 2024
- Published by Wiley in Health Expectations
- Vol. 27 (6) , e70059
Open AccessThe Value of Clinical Prediction Models in General Practice: A Qualitative Study Exploring the Perspectives of People With Lived Experience of Depression and General Practitioners
Introduction: Prediction models are increasingly being used to guide clinical decision making in primary care. There is a lack of evidence exploring the views of patients and general practitioners (GPs) in primary care around their use and implementation. We aimed to better understand the perspectives of GPs and people with lived experience of depression around the use of prediction models and communication of risk in primary care.Methods: Qualitative methods were used. Data were generated over 6 months (April to October 2022) through semi‐structured interviews with 23 people with lived experience of depression and 22 GPs. A multidisciplinary research team and Patient Advisory Group were involved throughout the study. Data were analysed inductively using thematic analysis.Results: GPs describe using prediction models in consultations only when the models are either perceived to be useful (e.g., because they help address an important clinical problem) or if GPs feel compelled to use them to meet financial or contractual targets. These two situations are not mutually exclusive, but if neither criterion is met, a model is unlikely to be used in practice. People with lived experience of depression and GPs reported that communication of model outputs should involve a combination of risk categories, numerical information and visualisations, with discussions being tailored to the individual patients involved. Risk prediction in a mental health context was perceived to be more challenging than for physical health conditions.Conclusion: Clinical prediction models are used in practice but thought must be given at the study development stage to how results will be presented and discussed with patients. Meaningful, embedded public and patient involvement and engagement are recommended when developing or implementing clinical prediction models.Patient or Public Contribution: We used a combination of embedded consultation and collaboration/co‐production in our approach to public and patient involvement in this study. A Patient Advisory Group made up of people with lived experience of depression were involved from study conception and contributed to study design, participant recruitment, interpretation of findings and dissemination (including in the preparation of this manuscript).
- Open Access
- 28 October 2024
- Published by BMJ in BMJ Mental Health
- Vol. 27 (1) , e301226
Development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
Background Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual’s risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention. Objective The objective was to develop and validate a prognostic model to predict risk of relapse of depression in primary care. Methods Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping, and generalisability was explored using internal–external cross-validation. Findings Residual depressive symptoms (OR: 1.13 (95% CI: 1.07 to 1.20), pConclusions We could not predict risk of depression relapse with sufficient accuracy in primary care data, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse. Clinical implications Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute-phase treatment or post remission. Where possible, this could be guided by the presence or absence of known prognostic factors (eg, residual depressive symptoms) and targeted towards these. Trial registration number NCT04666662.
- 28 October 2024
- Published by BMJ in BMJ Mental Health
- Vol. 27 (1) , e301226
Open AccessDevelopment and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
Background Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual’s risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention. Objective The objective was to develop and validate a prognostic model to predict risk of relapse of depression in primary care. Methods Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping, and generalisability was explored using internal–external cross-validation. Findings Residual depressive symptoms (OR: 1.13 (95% CI: 1.07 to 1.20), pConclusions We could not predict risk of depression relapse with sufficient accuracy in primary care data, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse. Clinical implications Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute-phase treatment or post remission. Where possible, this could be guided by the presence or absence of known prognostic factors (eg, residual depressive symptoms) and targeted towards these. Trial registration number NCT04666662.
- Open Access
- 20 September 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (753) , e292-e299
Role of primary care in depression relapse: a qualitative study
Background: Relapse contributes to the clinical and societal burden associated with depression. It is not well understood how relapse risk and prevention are managed and discussed between patients and GPs in primary care. Aim: To understand the extent to which relapse risk and prevention are discussed and managed in general practice. Design and setting: A qualitative study undertaken in general practice in the UK. Method: Participants were recruited through general practices. Data were generated using semi-structured interviews and analysed using thematic analysis. Patient and public involvement informed all aspects of the study. Results: Twenty-three people with lived experience of depression and 22 GPs were interviewed. The following three themes are presented in this paper: perceived determinants of depression course (participants viewed environmental, social, and personal factors as being most important); relapse risk and prevention (relapse was considered important but not consistently or routinely discussed in general practice consultations); and relationships and communication (participants discussed the key role of the GP–patient relationship). Conceptually, relapse was perceived as having limited meaning and usefulness in primary care, owing to the implication of an episodic, discrete course not recognised by many patients and an over-reliance on biomedical diagnosis. Longer-term follow-up and monitoring of depression could be improved in primary care. Conclusion: We provide an evidence-informed framework to improve practice systems and GP consultations to enhance longer-term care and support for people with depression. Going forwards, acute depression management could be optimised to include discussions of relapse risk and prevention. Brief, scalable relapse prevention interventions are needed for use in primary care.
- 20 September 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (753) , e292-e299
Open AccessRole of primary care in depression relapse: a qualitative study
Background: Relapse contributes to the clinical and societal burden associated with depression. It is not well understood how relapse risk and prevention are managed and discussed between patients and GPs in primary care. Aim: To understand the extent to which relapse risk and prevention are discussed and managed in general practice. Design and setting: A qualitative study undertaken in general practice in the UK. Method: Participants were recruited through general practices. Data were generated using semi-structured interviews and analysed using thematic analysis. Patient and public involvement informed all aspects of the study. Results: Twenty-three people with lived experience of depression and 22 GPs were interviewed. The following three themes are presented in this paper: perceived determinants of depression course (participants viewed environmental, social, and personal factors as being most important); relapse risk and prevention (relapse was considered important but not consistently or routinely discussed in general practice consultations); and relationships and communication (participants discussed the key role of the GP–patient relationship). Conceptually, relapse was perceived as having limited meaning and usefulness in primary care, owing to the implication of an episodic, discrete course not recognised by many patients and an over-reliance on biomedical diagnosis. Longer-term follow-up and monitoring of depression could be improved in primary care. Conclusion: We provide an evidence-informed framework to improve practice systems and GP consultations to enhance longer-term care and support for people with depression. Going forwards, acute depression management could be optimised to include discussions of relapse risk and prevention. Brief, scalable relapse prevention interventions are needed for use in primary care.
- Open Access
The development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
Background Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual’s risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention. Objective Develop and validate a prognostic model to predict risk of relapse of depression in primary care. Methods Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping and generalisability was explored using internal-external cross-validation. Findings Residual depressive symptoms [Odds ratio (OR): 1.13 (95% CI: 1.07-1.20), pConclusions We cannot currently predict risk of depression relapse with sufficient accuracy in a primary care setting, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse. Clinical implications Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute phase treatment or post-remission. Where possible, this could be guided by the presence or absence of known prognostic factors (e.g. residual depressive symptoms) and targeted towards these. What is already known on this topic Relapse contributes to the morbidity and burden associated with depression and, while there is robust research confirming predictors of relapse, individualised risk prediction is a challenge. What this study adds We found that it is not possible to accurately predict individualised risk of relapse using prognostic factors that are routinely collected and available in primary care. We found evidence to suggest that relationship status (not being in a relationship) is associated with increased risk of relapse and warrants confirmatory prognostic factor research. How this study might affect research, practice or policy Future prognosis research in this area should focus on exploring the feasibility of routinely measuring and documenting additional prognostic factors in primary care (for example, adverse childhood events, relationship status and social support) and including these in prognostic models. Until we can more accurately identify individuals at increased risk of relapse, commonly used acute-phase treatments could be optimised to better prepare for and mitigate the risk of relapse and there is a need for brief, scalable relapse prevention interventions that could be provided more widely.
Open AccessThe development and validation of a prognostic model to predict relapse in adults with remitted depression in primary care: secondary analysis of pooled individual participant data from multiple studies
Background Relapse of depression is common and contributes to the overall associated morbidity and burden. We lack evidence-based tools to estimate an individual’s risk of relapse after treatment in primary care, which may help us more effectively target relapse prevention. Objective Develop and validate a prognostic model to predict risk of relapse of depression in primary care. Methods Multilevel logistic regression models were developed, using individual participant data from seven primary care-based studies (n=1244), to predict relapse of depression. The model was internally validated using bootstrapping and generalisability was explored using internal-external cross-validation. Findings Residual depressive symptoms [Odds ratio (OR): 1.13 (95% CI: 1.07-1.20), pConclusions We cannot currently predict risk of depression relapse with sufficient accuracy in a primary care setting, using routinely recorded measures. Relationship status warrants further research to explore its role as a prognostic factor for relapse. Clinical implications Until we can accurately stratify patients according to risk of relapse, a universal approach to relapse prevention may be most beneficial, either during acute phase treatment or post-remission. Where possible, this could be guided by the presence or absence of known prognostic factors (e.g. residual depressive symptoms) and targeted towards these. What is already known on this topic Relapse contributes to the morbidity and burden associated with depression and, while there is robust research confirming predictors of relapse, individualised risk prediction is a challenge. What this study adds We found that it is not possible to accurately predict individualised risk of relapse using prognostic factors that are routinely collected and available in primary care. We found evidence to suggest that relationship status (not being in a relationship) is associated with increased risk of relapse and warrants confirmatory prognostic factor research. How this study might affect research, practice or policy Future prognosis research in this area should focus on exploring the feasibility of routinely measuring and documenting additional prognostic factors in primary care (for example, adverse childhood events, relationship status and social support) and including these in prognostic models. Until we can more accurately identify individuals at increased risk of relapse, commonly used acute-phase treatments could be optimised to better prepare for and mitigate the risk of relapse and there is a need for brief, scalable relapse prevention interventions that could be provided more widely.
- Open Access
Neurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder
There have been suggestions that Long COVID might be purely functional (meaning psychological) in origin. Labelling patients with neurological dysfunction in Long COVID as having functional neurological disorder (FND) in the absence of proper testing may be symptomatic of that line of thought. This practice is problematic for Long COVID patients, as motor and balance symptoms have been reported to occur in Long COVID frequently. FND is characterized by the presentation of symptoms that seem neurological but lack compatibility of the symptom with a neurological substrate. Although diagnostic classification according to the ICD-11 and DSM-5-TR is dependent predominantly on the exclusion of any other medical condition that could account for the symptoms, current neurological practice of FND classification allows for such comorbidity. As a consequence, Long COVID patients with motor and balance symptoms mislabeled as FND have no longer access to Long COVID care, whereas treatment for FND is seldom provided and is ineffective. Research into underlying mechanisms and diagnostic methods should explore how to determine whether motor and balance symptoms currently diagnosed as FND should be considered one part of Long COVID symptoms, in other words, one component of symptomatology, and in which cases they correctly represent FND. Research into rehabilitation models, treatment and integrated care are needed, which should take into account biological underpinnings as well as possible psychological mechanisms and the patient perspective.
Open AccessNeurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder
There have been suggestions that Long COVID might be purely functional (meaning psychological) in origin. Labelling patients with neurological dysfunction in Long COVID as having functional neurological disorder (FND) in the absence of proper testing may be symptomatic of that line of thought. This practice is problematic for Long COVID patients, as motor and balance symptoms have been reported to occur in Long COVID frequently. FND is characterized by the presentation of symptoms that seem neurological but lack compatibility of the symptom with a neurological substrate. Although diagnostic classification according to the ICD-11 and DSM-5-TR is dependent predominantly on the exclusion of any other medical condition that could account for the symptoms, current neurological practice of FND classification allows for such comorbidity. As a consequence, Long COVID patients with motor and balance symptoms mislabeled as FND have no longer access to Long COVID care, whereas treatment for FND is seldom provided and is ineffective. Research into underlying mechanisms and diagnostic methods should explore how to determine whether motor and balance symptoms currently diagnosed as FND should be considered one part of Long COVID symptoms, in other words, one component of symptomatology, and in which cases they correctly represent FND. Research into rehabilitation models, treatment and integrated care are needed, which should take into account biological underpinnings as well as possible psychological mechanisms and the patient perspective.
- Open Access
Identifying the top research priorities in medically not yet explained symptoms (MNYES): a James Lind Alliance priority setting partnership
Objectives This study establishes research priorities for medically not yet explained symptoms (MNYES), also known as persistent physical symptoms or medically unexplained symptoms, from the perspective of patients, caregivers and clinicians, in a priority setting partnership (PSP) following the James Lind Alliance (JLA) approach. Research into such symptoms in general has been poorly funded over the years and so far has been primarily researcher-led with minimal input from patients, caregivers and clinicians; and sometimes has been controversial. Design JLA PSP method. The PSP termed these symptoms MNYES. Methods The study was conducted according to the JLA’s detailed methodology for conducting priority setting exercises. It involved five key stages: defining the appropriate term for the conditions under study by the PSP Steering Group; gathering questions on MNYES from patients, caregivers and clinicians in a publicly accessible survey; checking these research questions against existing evidence; interim prioritisation in a second survey; and a final multi-stakeholder consensus meeting to determine the top 10 unanswered research questions using the modified nominal group methodology. Results Over 700 responses from UK patients, caregivers and clinicians were identified in the two surveys and charities contributed from a broad range of medical specialties and primary care. The final top 10 unanswered research questions cover, among others: treatment strategies, personalisation of treatment, collaborative care pathways, training for clinicians and outcomes that matter to patients. Interpretation The top 10 unanswered research questions are expected to generate much needed, relevant and impactful research into MNYES.
Open AccessIdentifying the top research priorities in medically not yet explained symptoms (MNYES): a James Lind Alliance priority setting partnership
Objectives This study establishes research priorities for medically not yet explained symptoms (MNYES), also known as persistent physical symptoms or medically unexplained symptoms, from the perspective of patients, caregivers and clinicians, in a priority setting partnership (PSP) following the James Lind Alliance (JLA) approach. Research into such symptoms in general has been poorly funded over the years and so far has been primarily researcher-led with minimal input from patients, caregivers and clinicians; and sometimes has been controversial. Design JLA PSP method. The PSP termed these symptoms MNYES. Methods The study was conducted according to the JLA’s detailed methodology for conducting priority setting exercises. It involved five key stages: defining the appropriate term for the conditions under study by the PSP Steering Group; gathering questions on MNYES from patients, caregivers and clinicians in a publicly accessible survey; checking these research questions against existing evidence; interim prioritisation in a second survey; and a final multi-stakeholder consensus meeting to determine the top 10 unanswered research questions using the modified nominal group methodology. Results Over 700 responses from UK patients, caregivers and clinicians were identified in the two surveys and charities contributed from a broad range of medical specialties and primary care. The final top 10 unanswered research questions cover, among others: treatment strategies, personalisation of treatment, collaborative care pathways, training for clinicians and outcomes that matter to patients. Interpretation The top 10 unanswered research questions are expected to generate much needed, relevant and impactful research into MNYES.
- Open Access
Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa
Objective To investigate the effectiveness of a complex behavioural intervention, ProLife, on tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking. Design Multicentre, individual, randomised controlled trial where participants were assigned (1:1) to the ProLife intervention or usual care. Setting 27 primary care clinics in South Africa. Participants 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or reported harmful/hazardous alcohol use. Interventions The intervention, delivered by lay health workers (LHWs), consisted of three brief motivational interviewing (MI) sessions, augmented with short message service (SMS) messages, targeting medication adherence, alcohol use and tobacco smoking. Outcome measures The primary outcome was successful versus unsuccessful TB treatment at 6–9 months, from TB records. Secondary outcomes were biochemically confirmed sustained smoking cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and antiretroviral therapy (ART) adherence and ART initiation, each measured at 3 and 6 months by questionnaires; and cure rates in patients who had bacteriology-confirmed TB at baseline, from TB records. Results Between 15 November 2018 and 31 August 2019, 574 participants were randomised to receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not differ significantly between intervention (67.8%) and control (70.1%; OR 0.9, 95% CI 0.64% to 1.27%). There was no evidence of an effect at 3 and 6 months, respectively, on continuous smoking abstinence (OR 0.65, 95% CI 0.37 to 1.14; OR 0.76, 95% CI 0.35 to 1.63), TB medication adherence (OR 1.22, 95% CI 0.52 to 2.87; OR 0.89, 95% CI 0.26 to 3.07), taking ART (OR 0.79, 95% CI 0.38 to 1.65; OR 2.05, 95% CI 0.80 to 5.27) or AUDIT scores (mean score difference 0.55, 95% CI −1.01 to 2.11; −0.04, 95% CI −2.0 to 1.91) and adjusting for baseline values. Cure rates were not significantly higher (OR 1.16, 95% CI 0.83 to 1.63). Conclusions Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs may not be an effective approach to improve TB outcomes. Trial registration number ISRCTN62728852.
Open AccessEffect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa
Objective To investigate the effectiveness of a complex behavioural intervention, ProLife, on tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking. Design Multicentre, individual, randomised controlled trial where participants were assigned (1:1) to the ProLife intervention or usual care. Setting 27 primary care clinics in South Africa. Participants 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or reported harmful/hazardous alcohol use. Interventions The intervention, delivered by lay health workers (LHWs), consisted of three brief motivational interviewing (MI) sessions, augmented with short message service (SMS) messages, targeting medication adherence, alcohol use and tobacco smoking. Outcome measures The primary outcome was successful versus unsuccessful TB treatment at 6–9 months, from TB records. Secondary outcomes were biochemically confirmed sustained smoking cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and antiretroviral therapy (ART) adherence and ART initiation, each measured at 3 and 6 months by questionnaires; and cure rates in patients who had bacteriology-confirmed TB at baseline, from TB records. Results Between 15 November 2018 and 31 August 2019, 574 participants were randomised to receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not differ significantly between intervention (67.8%) and control (70.1%; OR 0.9, 95% CI 0.64% to 1.27%). There was no evidence of an effect at 3 and 6 months, respectively, on continuous smoking abstinence (OR 0.65, 95% CI 0.37 to 1.14; OR 0.76, 95% CI 0.35 to 1.63), TB medication adherence (OR 1.22, 95% CI 0.52 to 2.87; OR 0.89, 95% CI 0.26 to 3.07), taking ART (OR 0.79, 95% CI 0.38 to 1.65; OR 2.05, 95% CI 0.80 to 5.27) or AUDIT scores (mean score difference 0.55, 95% CI −1.01 to 2.11; −0.04, 95% CI −2.0 to 1.91) and adjusting for baseline values. Cure rates were not significantly higher (OR 1.16, 95% CI 0.83 to 1.63). Conclusions Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs may not be an effective approach to improve TB outcomes. Trial registration number ISRCTN62728852.
- Open Access
- 11 January 2022
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 221 (2) , 448-458
Predicting relapse or recurrence of depression: systematic review of prognostic models
Background: Relapse and recurrence of depression are common, contributing to the overall burden of depression globally. Accurate prediction of relapse or recurrence while patients are well would allow the identification of high-risk individuals and may effectively guide the allocation of interventions to prevent relapse and recurrence.Aims: To review prognostic models developed to predict the risk of relapse, recurrence, sustained remission, or recovery in adults with remitted major depressive disorder.Method: We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2021. We included development and external validation studies of multivariable prognostic models. We assessed risk of bias of included studies using the Prediction model risk of bias assessment tool (PROBAST).Results: We identified 12 eligible prognostic model studies (11 unique prognostic models): 8 model development-only studies, 3 model development and external validation studies and 1 external validation-only study. Multiple estimates of performance measures were not available and meta-analysis was therefore not necessary. Eleven out of the 12 included studies were assessed as being at high overall risk of bias and none examined clinical utility.Conclusions: Due to high risk of bias of the included studies, poor predictive performance and limited external validation of the models identified, presently available clinical prediction models for relapse and recurrence of depression are not yet sufficiently developed for deploying in clinical settings. There is a need for improved prognosis research in this clinical area and future studies should conform to best practice methodological and reporting guidelines.
- 11 January 2022
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 221 (2) , 448-458
Open AccessPredicting relapse or recurrence of depression: systematic review of prognostic models
Background: Relapse and recurrence of depression are common, contributing to the overall burden of depression globally. Accurate prediction of relapse or recurrence while patients are well would allow the identification of high-risk individuals and may effectively guide the allocation of interventions to prevent relapse and recurrence.Aims: To review prognostic models developed to predict the risk of relapse, recurrence, sustained remission, or recovery in adults with remitted major depressive disorder.Method: We searched the Cochrane Library (current issue); Ovid MEDLINE (1946 onwards); Ovid Embase (1980 onwards); Ovid PsycINFO (1806 onwards); and Web of Science (1900 onwards) up to May 2021. We included development and external validation studies of multivariable prognostic models. We assessed risk of bias of included studies using the Prediction model risk of bias assessment tool (PROBAST).Results: We identified 12 eligible prognostic model studies (11 unique prognostic models): 8 model development-only studies, 3 model development and external validation studies and 1 external validation-only study. Multiple estimates of performance measures were not available and meta-analysis was therefore not necessary. Eleven out of the 12 included studies were assessed as being at high overall risk of bias and none examined clinical utility.Conclusions: Due to high risk of bias of the included studies, poor predictive performance and limited external validation of the models identified, presently available clinical prediction models for relapse and recurrence of depression are not yet sufficiently developed for deploying in clinical settings. There is a need for improved prognosis research in this clinical area and future studies should conform to best practice methodological and reporting guidelines.
- 15 November 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (11)
Interventions for preventing relapse or recurrence of major depressive disorder in adults in a primary care setting: a network meta-analysis
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: The aim is to assess, using network meta‐analysis (NMA), the effectiveness and safety of interventions for preventing relapse‐recurrence of depression in adults in a primary care setting. NMA is a technique for comparing three or more interventions simultaneously in a single analysis by combining both direct and indirect evidence across a network of studies. The objectives are to: estimate the relative effectiveness of pharmacological, psychological and other interventions to prevent relapse‐recurrence, compared with each other and controls (e.g. pill placebo, treatment as usual) on relapse‐recurrence outcomes and adverse events; assess the effect of interventions on quality of life outcomes and social and occupational functioning; estimate the relative ranking of included interventions on relapse‐recurrence, quality of life, and adverse events; summarise availability and principal findings of eligible economic evaluations.
- 15 November 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (11)
Interventions for preventing relapse or recurrence of major depressive disorder in adults in a primary care setting: a network meta-analysis
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: The aim is to assess, using network meta‐analysis (NMA), the effectiveness and safety of interventions for preventing relapse‐recurrence of depression in adults in a primary care setting. NMA is a technique for comparing three or more interventions simultaneously in a single analysis by combining both direct and indirect evidence across a network of studies. The objectives are to: estimate the relative effectiveness of pharmacological, psychological and other interventions to prevent relapse‐recurrence, compared with each other and controls (e.g. pill placebo, treatment as usual) on relapse‐recurrence outcomes and adverse events; assess the effect of interventions on quality of life outcomes and social and occupational functioning; estimate the relative ranking of included interventions on relapse‐recurrence, quality of life, and adverse events; summarise availability and principal findings of eligible economic evaluations.